HomeNewsIndiaReady to partner with interested countries for tech transfer, manufacture of COVID-19 vaccines: India

Ready to partner with interested countries for tech transfer, manufacture of COVID-19 vaccines: India

"While this issue is being deliberated in the WTO, we stand ready to partner with interested countries for the transfer of technology and manufacture of COVID-19 vaccines indigenously developed in India," Shringla said in his statement.

September 17, 2021 / 08:15 IST
Story continues below Advertisement
On the 243rd day of the COVID-19 vaccination drive, 37.47 lakh beneficiaries received their first shot and 27.04 lakh their second dose. (Representative image)
On the 243rd day of the COVID-19 vaccination drive, 37.47 lakh beneficiaries received their first shot and 27.04 lakh their second dose. (Representative image)

India said that while the issue of temporarily waiving patents on COVID-19 vaccines is being deliberated in the WTO, it stands ready to partner with interested countries for the transfer of technology and manufacture of its indigenously developed jabs.

Foreign Secretary Harsh Vardhan Shringla, participating in the Commonwealth Foreign Affairs Ministers’ Meeting on behalf of External Affairs Minister S Jaishankar, said that in order to address vaccine inequity and promote the interests of the developing world, several of whom are members of the Commonwealth, India, along with South Africa, has proposed the TRIPS waiver for vaccine production in developing countries.

Story continues below Advertisement

"While this issue is being deliberated in the WTO, we stand ready to partner with interested countries for the transfer of technology and manufacture of COVID-19 vaccines indigenously developed in India," Shringla said in his statement.

Under the Quad framework, India is also partnering with Australia, Japan and the United States to expand the vaccine manufacturing capacity in India, to assist countries in the Indo-Pacific region, again several of whom are small island states and members of the Commonwealth, he said.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show